Moleculin Biotech Pares Gains After Securities-Purchase Agreement

Dow Jones

Feb 26, 2025

By Josh Beckerman

Shares of Moleculin Biotech pared earlier gains after the pharmaceutical company announced a $3.5 million registered direct offering and concurrent private placement.

The stock was recently up 14%, to $1.22, midday Tuesday. Shares had risen to an intraday high of $1.64 following Monday's withdrawal of a December filing for public offering of stock and warrants.

Volume was more than 33.4 million shares, compared with a 65-day average of 4.3 million.

The company said Tuesday afternoon that it entered an agreement with an institutional investor to sell 3.27 million shares or pre-funded warrants in lieu thereof, and 6.54 million warrants, at a combined price of $1.07 a share and accompanying warrants.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

February 25, 2025 13:09 ET (18:09 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2514013017"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514013017\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514013017?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-26 02:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514013017","market":"fut","top_or_hot":-1,"title":"Moleculin Biotech Pares Gains After Securities-Purchase Agreement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Moleculin Biotech pared earlier gains after the pharmaceutical company announced a $3.5 million registered direct offering and concurrent private placement. \n</p>\n<p>\n  The stock was recently up 14%, to $1.22, midday Tuesday. Shares had risen to an intraday high of $1.64 following Monday's withdrawal of a December filing for public offering of stock and warrants. \n</p>\n<p>\n  Volume was more than 33.4 million shares, compared with a 65-day average of 4.3 million. \n</p>\n<p>\n  The company said Tuesday afternoon that it entered an agreement with an institutional investor to sell 3.27 million shares or pre-funded warrants in lieu thereof, and 6.54 million warrants, at a combined price of $1.07 a share and accompanying warrants. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2025 13:09 ET (18:09 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moleculin Biotech Pares Gains After Securities-Purchase Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMoleculin Biotech Pares Gains After Securities-Purchase Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-26 02:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Moleculin Biotech pared earlier gains after the pharmaceutical company announced a $3.5 million registered direct offering and concurrent private placement. \n</p>\n<p>\n  The stock was recently up 14%, to $1.22, midday Tuesday. Shares had risen to an intraday high of $1.64 following Monday's withdrawal of a December filing for public offering of stock and warrants. \n</p>\n<p>\n  Volume was more than 33.4 million shares, compared with a 65-day average of 4.3 million. \n</p>\n<p>\n  The company said Tuesday afternoon that it entered an agreement with an institutional investor to sell 3.27 million shares or pre-funded warrants in lieu thereof, and 6.54 million warrants, at a combined price of $1.07 a share and accompanying warrants. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2025 13:09 ET (18:09 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2514013017","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514013017","pubTimestamp":1740506940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Moleculin Biotech pared earlier gains after the pharmaceutical company announced a $3.5 million registered direct offering and concurrent private placement.The stock was recently up 14%, to $1.22, midday Tuesday. Shares had risen to an intraday high of $1.64 following Monday's withdrawal of a December filing for public offering of stock and warrants.Volume was more than 33.4 million shares, compared with a 65-day average of 4.3 million.The company said Tuesday afternoon that it entered an agreement with an institutional investor to sell 3.27 million shares or pre-funded warrants in lieu thereof, and 6.54 million warrants, at a combined price of $1.07 a share and accompanying warrants.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MBRX":"Moleculin Biotech, Inc."},"translate_title":"Moleculin Biotech在证券购买协议后削减涨幅","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MBRX":1},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Shares of Moleculin Biotech pared earlier gains after the pharmaceutical company announced a $3.5 million registered direct offering and concurrent private placement. \n\n\n  The stock was recently up 14%, to $1.22, midday Tuesday. Shares had risen to an intraday high of $1.64 following Monday's withdrawal of a December filing for public offering of stock and warrants. \n\n\n  Volume was more than 33.4 million shares, compared with a 65-day average of 4.3 million. \n\n\n  The company said Tuesday afternoon that it entered an agreement with an institutional investor to sell 3.27 million shares or pre-funded warrants in lieu thereof, and 6.54 million warrants, at a combined price of $1.07 a share and accompanying warrants. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2025 13:09 ET (18:09 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}